contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-2701-netcompany-og-ascelia-pharma-ab

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Netcompany Group is an IT company. The company specializes in consulting services and business-critical IT solutions, including internal systems development, big data management, mobile apps, analysis services, and E-commerce solutions. The customers can be found in several sectors, including finance, industry, authorities, and institutes. Netcompany was founded in 2000 and has its headquarters in Copenhagen.

Netcompany Group

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Ascelia Pharma er et svensk biotechselskab med fokus på lægemidler til cancer behandlinger. Selskabet udvikler og kommercialiserer lægemidler, der er målrettet mod medicinske behov som endnu ikke bliver opfyldt og har en klar udviklings- og markedsvej. Ascelia Pharma har to pipeline-produkter, nemlig Orviglance og Oncoral. Orviglance (tidligere Mangoral) er selskabets hovedprodukt. Orviglance er i et fase 3-studie og estimeres at blive godkendt i 2023. Orviglance er et nyt kontrastmiddel til MR-scanning, udviklet til at forbedre påvisning og visualisering af leverlæsioner (inklusiv lever metastaser – og primære tumorer) hos patienter med nedsat nyrefunktion. Derudover har selskabet et fase-2 studie produkt i Oncoral som estimeres at have en færdiggørelsesdato i 2024. Oncoral er en tablet som indtages dagligt med en etableret potent anti-tumor-effekt – selv i svært behandlende kræftformer med potentiale for at tilbyde bedre patientresultater. Oncoral øger patientsikkerheden i og med patienten får en mildere dosis dagligt i form af en tablet, fremfor løbende intravenøse højdosis infusioner på hospitalet. English:  Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments.  They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance (Former working name Mangoral) is their main product which is a phase 3 study with an estimated completion date in June 2022. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a phase 2 study with an estimated completion date in 2024. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma

Dagens aktienyheder med Netcompany og Ascelia Pharma AB

Dagens aktienyheder 27/01: <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:215128" data-guid="6" data-object-urn="urn:li:organization:215128" data-original-text="Netcompany" data-test-ql-mention="true">Netcompany</a> og <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:2606403" data-guid="7" data-object-urn="urn:li:organization:2606403" data-original-text="Ascelia Pharma AB" data-test-ql-mention="true">Ascelia Pharma AB</a>
Netcompany offentligg&#xf8;r efter planen sit &#xe5;rsregnskab for 2024 i morgen &#x2013; tirsdag d. 28. januar 2024. For hele 2024 lyder den aktuelle guidance fra Netcompany p&#xe5; en oms&#xe6;tningsv&#xe6;kst p&#xe5; 7-10%, imens adjusted EBITDA-margin ventes at lande i intervallet 15-18%. For 2025 lyder konsensus blandt de samme 8 analytikere p&#xe5; en oms&#xe6;tning p&#xe5; DKK 7.106 mio., svarende til en v&#xe6;kst p&#xe5; ca. 8,5% sammenholdt med 2024 estimaterne. EBITDA ventes at lande p&#xe5; DKK 1.360 mio. Det svarer til en margin p&#xe5; 18,4%, og en v&#xe6;kst p&#xe5; 17,0% i forhold til 2024 estimaterne. P&#xe5; fredag d. 31. januar kl. 11.00 har vi forn&#xf8;jelsen at invitere til en pr&#xe6;sentation af regnskabet med CFO Thomas Johansen, der ogs&#xe5; vil svare p&#xe5; sp&#xf8;rgsm&#xe5;l fra publikum. Tilmelding her: https://www.inderes.dk/videos/netcompany-praesentation-af-arsregnskabet-for-2024
Ascelia Pharma: Selskabet har til morgen offentliggjort at de deltager p&#xe5; den &#xe5;rlige ESGAR (European Society of Gastrointestinal and Abdominal Radiology) konference i Amsterdam den 13-16 maj 2025 med tre s&#xe5;kaldte poster pr&#xe6;sentationer p&#xe5; Orviglance SPARKLE fase 3 data. L&#xe6;s meddelelsen her: https://www.ascelia.com/mfn_news/ascelia-pharma-announces-acceptance-of-three-scientific-abstracts-with-sparkle-phase-3-data-at-the-european-society-of-gastrointestinal-and-abdominal-radiology-annual-meeting/
&#xd8;rsted var aktien i v&#xe6;lten i sidste uge med nye store US nedskrivninger. I vores programserie aktier i v&#xe6;lten s&#xe5; vi ind p&#xe5; blandt andet hvordan aktien er v&#xe6;rdisat, og hvad er det, som driver k&#xf8;bere og s&#xe6;lgere i aktien lige. Se videoen her: https://www.inderes.dk/videos/aktier-i-vaelten-orsted-fremtidige-projekter-er-naesten-domt-ude-er-det-rigtigt
I sidste uges aktier med Friis s&#xe5; vi p&#xe5; den h&#xe6;sbl&#xe6;sende f&#xf8;rste uge med Trump ved roret, og om vi overhovedet kunne l&#xe6;re noget af det, eller blot m&#xe5; leve fra dag til dag: desuden s&#xe5; vi p&#xe5; om h&#xe5;b er blevet et investeringstema, eller der er andet som driver de europ&#xe6;iske aktier, der har taget f&#xf8;rertr&#xf8;jen i starten af 2025. https://www.inderes.dk/videos/aktier-med-friis-uge-4-2025
Disclaimer:&#xa0;<a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:54143576" data-guid="5" data-object-urn="urn:li:organization:54143576" data-original-text="HC Andersen Capital" data-test-ql-mention="true">HC Andersen Capital</a> modtager betaling fra de n&#xe6;vnte selskaber for en digital IR/Corporate Visibility abonnementsaftale.
/Jesper Thomsen kl. 08:59 d. 27/01-2025